Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01843062
Previous Study | Return to List | Next Study

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (ASTRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01843062
Recruitment Status : Terminated (Study was terminated based on the findings of primary analysis at 18 months post-RAI treatment. Patients pending 3 year follow up had end of study phone call.)
First Posted : April 30, 2013
Results First Posted : April 22, 2019
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.

Condition or disease Intervention/treatment Phase
Differentiated Thyroid Cancer Drug: Selumetinib Drug: Placebo Drug: Radioactive Iodine Therapy Phase 3

Detailed Description:
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 233 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Actual Study Start Date : August 27, 2013
Actual Primary Completion Date : May 18, 2018
Actual Study Completion Date : March 6, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Selumetinib
Selumetinib plus Radioactive Iodine Therapy
Drug: Selumetinib
3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period

Drug: Radioactive Iodine Therapy
A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)

Placebo Comparator: Placebo
Placebo plus Radioactive Iodine Therapy
Drug: Placebo
3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period

Drug: Radioactive Iodine Therapy
A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)




Primary Outcome Measures :
  1. Complete Remission Rate (Expressed as Percentage of Patients in Complete Remission) at 18 Months Post-RAI Treatment; ITT Analysis Set [ Time Frame: At 18 months post-RAI treatment ]

    Patients were defined to be in complete remission if all of the following criteria were demonstrated:

    1. Serum thyroglobulin (Tg) levels <1 nanograms / millilitre (ng/mL) during rhTSH stimulation, in the absence of interfering Tg antibodies, as assessed by standardised central laboratory analysis.
    2. No confirmed evidence of thyroid cancer on neck ultrasound, as assessed by investigator site review.
    3. No confirmed radiological evidence of thyroid cancer, as assessed by blinded independent central review.
    4. No histopathological evidence of thyroid cancer on fine needle aspiration (FNA)/biopsy when performed, as assessed by investigator site review.
    5. No further thyroid cancer therapy was administered in the first 18 months following the initial RAI treatment.


Secondary Outcome Measures :
  1. Complete Remission Rate (Expressed as Percentage of Patients in Complete Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive [ Time Frame: At 18 months post-RAI treatment ]

    Patients were defined to be in complete remission if all of the following criteria were demonstrated:

    1. Serum Tg levels <1 ng/mL during rhTSH stimulation, in the absence of interfering Tg antibodies, as assessed by standardised central laboratory analysis.
    2. No confirmed evidence of thyroid cancer on neck ultrasound, as assessed by investigator site review.
    3. No confirmed radiological evidence of thyroid cancer, as assessed by blinded independent central review.
    4. No histopathological evidence of thyroid cancer FNA/biopsy when performed, as assessed by investigator site review.
    5. No further thyroid cancer therapy was administered in the first 18 months following the initial RAI treatment.

  2. Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; ITT Analysis Set [ Time Frame: At 18 months post-RAI treatment ]

    Patients were defined to be in clinical remission if all of the following criteria were demonstrated:

    1. Serum Tg levels <1 ng/mL during rhTSH stimulation, in the absence of interfering Tg antibodies, as assessed by standardised central laboratory analysis.
    2. No confirmed evidence of thyroid cancer on neck ultrasound, as assessed by investigator site review.
    3. No evidence of thyroid cancer on diagnostic whole body scan (WBS), as assessed by blinded independent central review.
    4. No histopathological evidence of thyroid cancer on FNA/biopsy when performed to clarify equivocal ultrasound findings, as assessed by investigator site review.
    5. No further thyroid cancer therapy was administered in the first 18 months following the initial RAI treatment.

  3. Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive [ Time Frame: At 18 months post-RAI treatment ]

    Patients were defined to be in clinical remission if all of the following criteria were demonstrated:

    1. Serum Tg levels <1 ng/mL during rhTSH stimulation, in the absence of interfering Tg antibodies, as assessed by standardised central laboratory analysis.
    2. No confirmed evidence of thyroid cancer on neck ultrasound, as assessed by investigator site review.
    3. No evidence of thyroid cancer on diagnostic WBS, as assessed by blinded independent central review.
    4. No histopathological evidence of thyroid cancer on FNA/biopsy when performed to clarify equivocal ultrasound findings, as assessed by investigator site review.
    5. No further thyroid cancer therapy was administered in the first 18 months following the initial RAI treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Differentiated thyroid cancer Tumor >4 cm, or Gross extra-thyroid extension, or 1 lymph node >1 cm, or 5 or more lymph nodes of any size Previous thyroidectomy Must be able to receive radioactive iodine therapy Must be able to receive Thyroid Stimulating Hormone suppression

Exclusion criteria:

Metastaic disease Anaplastic thyroid cancer, medullary thyroid cancer or Hurthle cell carcinoma Presence of anti-Tg antibodies Previous treatment with any radiation Unresolved toxicity ≥ common terminology criteria for adverse event Grade 2


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01843062


Locations
Layout table for location information
United States, Alabama
Research Site
Birmingham, Alabama, United States, 35233
United States, Arkansas
Research Site
Little Rock, Arkansas, United States, 72205
United States, California
Research Site
Los Angeles, California, United States, 90048
Research Site
Torrance, California, United States, 90502
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, District of Columbia
Research Site
Washington, District of Columbia, United States, 20010
United States, Massachusetts
Research Site
Boston, Massachusetts, United States, 02114
Research Site
Boston, Massachusetts, United States, 02215
United States, New York
Research Site
New York, New York, United States, 10029
Research Site
New York, New York, United States, 10065
United States, North Carolina
Research Site
Durham, North Carolina, United States, 27710
United States, Ohio
Research Site
Cincinnati, Ohio, United States, 45219
United States, Oregon
Research Site
Portland, Oregon, United States, 97239
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19014
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37232-8148
Brazil
Research Site
Barretos, Brazil, 14784-400
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Denmark
Research Site
Odense C, Denmark, 5000
France
Research Site
Angers Cedex 01, France, 49033
Research Site
Bordeaux Cedex, France, 33076
Research Site
Caen Cedex 5, France, 41076
Research Site
Lyon, France
Research Site
Toulouse Cedex 9, France, 31059
Research Site
Villejuif Cedex, France, 94805
Germany
Research Site
Augsburg, Germany, 86156
Research Site
Essen, Germany, 45122
Research Site
Leipzig, Germany, 04103
Italy
Research Site
Catania, Italy, 95122
Research Site
Napoli, Italy, 80131
Research Site
Pisa, Italy, 56124
Research Site
Roma, Italy, 00161
Poland
Research Site
Gliwice, Poland, 44-101
Research Site
Kielce, Poland, 25-734
Research Site
Poznań, Poland, 60-355
Research Site
Warszawa, Poland, 02-507
Research Site
Warszawa, Poland, 02-781
Research Site
Zgierz, Poland, 95-100
Sweden
Research Site
Göteborg, Sweden, 413 45
Research Site
Linköping, Sweden, 581 85
Research Site
Lund, Sweden, 221 85
Research Site
Stockholm, Sweden, 171 76
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Alan Ho, M.D., PHD Memorial Sloan Kettering Cancer Centre, 1275 York Avenue, New York, NY 10065.
Study Director: Tracy C Cunningham, M.D Melbourn Science Park, Cambridge Road, Melbourn, Hertfordshire, SG8 6HB, UK
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] January 24, 2013
Statistical Analysis Plan  [PDF] April 4, 2018

Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01843062    
Other Study ID Numbers: D1532C00065
2013-000423-14 ( EudraCT Number )
First Posted: April 30, 2013    Key Record Dates
Results First Posted: April 22, 2019
Last Update Posted: August 28, 2019
Last Verified: August 2019
Keywords provided by AstraZeneca:
Selumetinib, Differentiated Thyroid Cancer , AZD6244
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms